Biomedical Sciences and Clinical Medicine https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ <table style="height: 871px;" border="0" width="631" cellspacing="0" cellpadding="0"> <tbody> <tr> <td valign="top" width="100%"> <p><img src="https://he01.tci-thaijo.org/public/site/images/bscm_medcmu/cover-issue-18547-en-us.jpg" /></p> </td> </tr> <tr> <td valign="top" width="100%"> <h2>Welcome to the Biomedical Sciences and Clinical Medicine (BSCM)</h2> <p>It is my great pleasure to invite you to explore our journal, where we are committed to fostering inclusivity, scientific rigor, and excellence. At BSCM, our mission is to advance biomedical knowledge and clinical practice. We aim to bridge the gap between research and clinical application, ensuring that innovative discoveries translate into meaningful benefits for patients and healthcare systems worldwide. Serving as a hub for multidisciplinary collaboration, the journal brings together researchers, clinicians, and scholars from across the globe to exchange groundbreaking research and pioneering ideas that drive progress in medical science.</p> <h3>International Recognition</h3> <ul> <li class="show">Since 2022, the journal has been indexed in Scopus and is currently ranked Q4 in the subject areas of Health Professions: Pharmacy, Health Professions (miscellaneous), Medicine (miscellaneous), and Nursing (miscellaneous).</li> <li class="show">BSCM has recently been officially accepted for inclusion in the Directory of Open Access Journals (DOAJ).</li> <li class="show">All articles published from 2022 onwards are now freely accessible through the DOAJ, further enhancing the visibility and accessibility of the research we publish.</li> </ul> <h3>Looking Ahead: Important Developments Starting Issue 1, 2026</h3> <p>We are pleased to announce several important developments to better serve our authors and readers:</p> <ul> <li class="show">The number of articles per issue will increase from 9 to 15, reflecting the growth in high-quality submissions.</li> <li class="show">The Author Guidelines have been updated to require a graphical abstract.</li> <li class="show">The “Back Matters” section has been expanded from three to seven components: <ul> <li class="show">Acknowledgments</li> <li class="show">Funding</li> <li class="show">Conflicts of Interest</li> <li class="show">Author Contributions</li> <li class="show">Data Availability Statement</li> <li class="show">Institutional Review Board Statement</li> <li class="show">Informed Consent Statement</li> </ul> </li> <li class="show">Editorial workflows are being streamlined through revised Standard Operating Procedures to accelerate peer review and publication timelines.</li> </ul> <p>We warmly encourage you to consider submitting your work to BSCM. We welcome original articles, review articles, case reports, and short communications that contribute significant new insights. Please consult the updated Submission Checklist to ensure your manuscript meets our standards.</p> <p>These initiatives reflect our commitment to continuous improvement and to establishing BSCM as a trusted, internationally recognized platform for impactful biomedical and clinical research. Together, with your insights and contributions, we can continue advancing science for the benefit of global health.</p> </td> </tr> </tbody> </table> en-US pornngarm.d@cmu.ac.th (Pornngarm Dejkriengkraikul, PhD) suree.s@cmu.ac.th (Suree Sirisupa) Fri, 06 Feb 2026 14:58:18 +0700 OJS 3.3.0.8 http://blogs.law.harvard.edu/tech/rss 60 Visual-Vestibular Rehabilitation Using Orthoptic and Vestibulo-Ocular Reflex Training in Parinaud Syndrome: A Case Report https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/282549 <p>Parinaud syndrome, or dorsal midbrain syndrome, is a rare neuro-ophthalmological disorder characterized by vertical gaze palsy, convergence-retraction nystagmus, light-near dissociation, and impaired convergence. Rehabilitation literature has primarily focused on motor outcomes in stroke, with limited evidence on visual rehabilitation in this Syndrome. A 39-year-old female presented with acute thalamic-midbrain hemorrhage and developed Parinaud Syndrome with vertical gaze palsy, convergence-retraction nystagmus, diplopia, and impaired near point of convergence. A structured visual-vestibular rehabilitation protocol was implemented, consisting of orthoptic training (pencil push-ups, stereogram fusion, saccadic tracking, smooth pursuits) and vestibulo-ocular reflex (VOR) training (gaze stabilization drills). The program was delivered for 4 weeks, 5 sessions per week. The patient showed partial restoration of upward gaze, improved convergence, reduced diplopia, and enhanced gaze stability. Near point of convergence improved, facilitating better reading ability and daily visual tasks with less fatigue. Functionally, she reported greater independence and confidence in activities requiring visual control. This case demonstrates the effectiveness of targeted visual-vestibular rehabilitation in Parinaud Syndrome, highlighting the role of orthoptic and vestibulo-ocular reflex exercises in improving ocular motility and functional vision. Future studies exploring digital eye-tracking and virtual reality may further enhance rehabilitation outcomes in this rare condition. </p> priyanka jeyaraj, Vanitha Jayaraj, Prathap Suganthirababu Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/282549 Fri, 10 Apr 2026 00:00:00 +0700 Etoricoxib in the 21st Century: An Old Molecule With New Possibilities https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/279311 <p>Chronic pain conditions, including osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), and acute gouty arthritis (AGA) are responsible for a substantial proportion of global disabilities and healthcare burdens. Etoricoxib, a selective cyclooxygenase-2 (COX) inhibitor, has shown better efficacy in these conditions due to its anti-inflammatory and analgesic properties. Its pharmacokinetic properties allow for rapid absorption and a long half-life, the latter enabling once-daily dosing, which has the impact of enhancing both adherence and symptom relief. Recent pharmacological investigation has evidenced the efficacy etoricoxib intervention in cases of other indications such as dental pain, low back pain (LBP), and postoperative analgesia. Clinical trials and meta-analyses have revealed etoricoxib’s superiority over traditional non-steroidal anti- inflammatory drugs (NSAIDs) such as ibuprofen. Novel delivery systems like nanostructured lipid carriers have been proven with to have improved anti-inflammatory effects and decreased cardiotoxicity in preclinical studies. Etoricoxib has shown synergistic outcomes with combination therapies of etoricoxib with tramadol, pregabalin, or thiocolchicoside in the treatment of both acute as well as chronic musculoskeletal pain. This article assembles the latest therapeutic advances and clinical and safety information on etoricoxib, highlighting its emerging role as an important drug in personalized management of pain and inflammation.</p> Mohamamd Anas Ansari, Arun Kumar Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/279311 Mon, 16 Mar 2026 00:00:00 +0700 Is Tui Na a Promising Approach for Autoimmune Diseases? A Review of Clinical Studies and Mechanisms https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/278880 <p>Autoimmune diseases, characterized by immune system dysfunction targeting healthy tissues, affect millions worldwide. While conventional treatments have advanced, unmet needs persist. Tui Na, a traditional Chinese massage therapy, has gained attention as a potential complementary treatment. This review explores Tui Na’s role in managing autoimmune conditions. A comprehensive literature search was conducted to identify studies investigating the use of Tui Na for autoimmune diseases in several databases. The available evidence suggests that Tui Na may offer potential benefits for individuals with autoimmune diseases. Studies have reported improvements in pain, fatigue, and overall well-being. Combining Tui Na with conventional treatments has often yielded enhanced outcomes. However, the evidence base is limited by a paucity of high-quality rando-mized controlled trials. Tui Na’s potential as a complementary therapy for autoimmune diseases is promising. Its ease of application and reported benefits warrant further exploration. However, the underlying mechanisms remain unclear, and the evidence base is insufficient to establish definitive recommendations. Future research should focus on rigorous study designs, larger sample sizes, and mechanistic investigations. Integrating Tui Na into comprehensive care plans requires careful consideration of patient-specific needs and potential interactions with conventional treatments. In conclusion, Tui Na shows promise as a complementary therapy for autoimmune diseases, offering potential benefits in symptom management and quality of life. While preliminary findings are encouraging, robust research is needed to establish its efficacy and safety</p> Helena Silva, Andreia Santos, Alexandra Monteiro, Inês Reis Sousa, Jorge Magalhães Rodrigues Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/278880 Mon, 16 Mar 2026 00:00:00 +0700 Association Between Polypharmacy and Frailty in Elderly Patients Receiving Care at a Public Hospital in South India https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275516 <p><strong>Objective</strong> This study analyses the impact of polypharmacy on frailty among the elderly patients visiting the public sector hospitals. The present study was done to assess the frailty status of the elderly patients and to see whether the individuals with polypharmacy exhibited more frailty when compared to those without polypharmacy.</p> <p><strong>Methods</strong> This is a case-control study that included 488 participants age 60 years and above who visited the general medicine department of Public Hospital Ooty, India. Polypharmacy was defined as the concomitant use of 5 or more medications. Frailty status of the participants was assessed using the Tilburg Frailty Indicator.</p> <p><strong>Results</strong> Polypharmacy was found to be present in 34.42% of cases. The prevalence of frailty was significantly higher in the polypharmacy group, affecting 41.07% of the study participants. Finally, three variables emerged as influential predictors of polypharmacy namely, 3 or more diseases (AOR 6.303, Cl 4.009-9.911, <em>p</em> &lt; 0.0001), unsatisfied sleep status (AOR 1.669, Cl 1.068-2.606, <em>p</em> = 0.01), and people taking frailty causing drugs (AOR 4.328, Cl 2.628-7.128, <em>p</em> = 0.003). Additionally, there was a moderate relationship between modified lifestyle (smoking, alcohol consumption) and polypharmacy.</p> <p><strong>Conclusions</strong> The results suggest that polypharmacy is linked with frailty among the elderly population, highlighting the importance of clinician awareness of these factors. </p> Hunsur Nagendra Vishwas, Shalini Tulasedas, Mohana Vishnu Varadhan Sivakumar, Gurulakshmi Ayyanar, Naveena Nagarajan, Balaji Sivasubramaniam, Arthi S, Sivasankaran Ponnusankar Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275516 Fri, 06 Feb 2026 00:00:00 +0700 Efficacy of Lidocaine/Prilocaine Cream During Dry Needling of Upper Trapezius Myofascial Trigger Points: A Double-blinded Randomized Controlled Trial https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/278835 <p><strong>Objective</strong> This study aimed to evaluate the efficacy of a eutectic mixture of local anesthetics (EMLA) cream in reducing pain during dry needling (DN) of active myofascial trigger points (MTrP) in the upper trapezius muscle.</p> <p><strong>Methods </strong>This prospective, randomized, double-blind, placebo-controlled trial was conducted with participants aged 20 years and older who had active MTrP in the upper trapezius muscle. Recruitment occurred from 11 July 2023 to 4 March 2024. Participants were randomly assigned to receive either EMLA cream (n = 32) or a placebo cream (n = 32) which was applied over the active MTrP 60 minutes prior to the DN procedure. After the DN procedure, patients rated their pain using a 100-mm visual analog scale during DN (VAS<sub>TrP</sub>) as the primary outcome and during the needle’s skin penetration (VAS<sub>skin</sub>) as the secondary outcome.</p> <p><strong>Results </strong>Patients in the EMLA group reported significantly lower scores for VAS<sub>TrP</sub> and VAS<sub>skin</sub> than those in the placebo group (<em>p</em> &lt; 0.05). Specifically, 53.1% of patients in the EMLA group reported ‘moderate to severe pain’ according to VAS<sub>TrP</sub>, significantly lower than the 78.10% in the placebo group (<em>p</em> = 0.035). Moreover, 65.63% of patients in the EMLA group reported ‘no pain’ on the VAS<sub>skin</sub> scale, compared to just 15.63% in the placebo group (<em>p</em> &lt; 0.001). Importantly, no significant adverse events associated with EMLA were observed.</p> <p><strong>Conclusion </strong>EMLA cream is effective in providing analgesia during DN of an active MTrP in the upper trapezius muscle. </p> Pimpika Fuktongphan, Thong Phonghanyudh, Chanwit Phongamwong Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/278835 Fri, 10 Apr 2026 00:00:00 +0700 Biochemical and Genetic Determinants of Early Cardiovascular and Hepatic Dysfunction: A Focus on ADIPOQ Expression https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/281381 <p><strong>Objective</strong> Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) frequently coexist due to common metabolic dysfunctions such as insulin resistance, chronic inflammation, and dyslipidemia. Adipo-nectin, encoded by the <em>ADIPOQ</em> gene, is an anti-inflammatory adipokine vital for glucose and lipid regulation. Reduced adiponectin levels and certain <em>ADIPOQ</em> gene variants (e.g., rs266729, rs2241766) have been linked to both NAFLD and CVD progression. This study aims to evaluate the association between <em>ADIPOQ</em> gene expression and early biochemical markers of hepatic and cardiovascular dysfunction.</p> <p><strong>Methods</strong> A case-control study (n = 300) was conducted in Thiruvananthapuram, Kerala, India (2022-2024), analyzing blood samples for fasting blood sugar (FBS), lipid profile, malondialdehyde (MDA), interleukin-6 (IL-6), and <em>ADIPOQ</em> expression (RT-PCR). Statistical analyses included receiver operating characteristic (ROC) curves and quantile regression using Stata 17.0.</p> <p><strong>Results</strong> Cases exhibited significantly elevated FBS, triglycerides (TG), low-density lipoprotein (LDL), MDA, and IL-6, along with reduced high- density lipoprotein (HDL) and adiponectin levels (<em>p</em> &lt; 0.05). ADIPOQ gene expression was markedly downregulated, particularly in individuals with both NAFLD and CVD. A positive correlation was observed between <em>ADIPOQ</em> expression and HDL, and a negative correlation with IL-6. Reduced <em>ADIPOQ</em> expression showed an association with risk in unadjusted analysis, but this association was not statistically significant after adjustment (OR = 0.0220). Nevertheless, ROC analysis indicated potential diagnostic utility.</p> <p><strong>Conclusions</strong> Reduced ADIPOQ expression is significantly associated with early metabolic and inflammatory markers in NAFLD and CVD. These findings highlight the potential utility of ADIPOQ as a biomarker for early detection and targeted prevention strategies in at-risk populations. </p> Rachana Raveendrana, A Josephine , V Sureka , P Kalaiselvi , Vishnu M G, Suresh Kumar K S, Simi Skariah, Manjusha K, Sebastian J Pengiparambil , Joby P Jose, Romi K S, Sony Peter , Dinesh Roy D Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/281381 Fri, 06 Feb 2026 00:00:00 +0700 Prevalence of Alcohol and Drugs in Fatal Road Traffic Injuries (RTIs) in a Thai Population Between 2018 and 2023 https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/281327 <p><strong>Objective</strong> To determine and compare the prevalence of alcohol, drugs of abuse and medicines in fatal road traffic injuries (RTIs) in Thailand from 2018 through 2023.</p> <p><strong>Methods</strong> A retrospective study was conducted of fatal RTI cases sent for autopsy at the Department of Forensic Medicine, Siriraj Hospital, Mahidol University from 2018 through 2023. Subject data, including sex, age, type of RTI case, blood alcohol concentration (BAC), and urine drug profile, were collected. Descriptive statistics, Chi-square tests, Mann–Whitney U tests, and Kruskal–Wallis H tests were performed as appropriate.</p> <p><strong>Results</strong> From 2018 through 2023 a total of 1,979 fatal RTI cases were included in this study. Of those cases, 1,649 were male (83.3%) and the mean subject age was 37.3 years. The yearly prevalence of driving under the influence (DUI) of alcohol (BAC &gt; 50 mg/dL) during the study period was between 45.80% and 53.40% with the exception of 2022, which showed a significant increase at 57.10% (<em>p</em> &lt; 0.05). The prevalence of drugs in 2023 was 21.00%, a significant difference compared with the prevalence in 2018 of 13.70% (<em>p</em> &lt; 0.05). The prevalence of cannabis use showed an increasing trend, with a statistically significant increase in 2023 (<em>p</em> &lt; 0.05). The preva-lence of multiple drug use also significantly increased over the study period, particularly in 2023 (<em>p</em> &lt; 0.05).</p> <p><strong>Conclusions</strong> The prevalence of drugs of abuse and medication in fatal RTI cases markedly increased over the study period, particularly in 2023. There was a significant increase in cannabis use and poly-drug use in fatal RTI cases over the period, especially in 2023. </p> Peerayuht Phuangphung, Patcharanun Chulamanee Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/281327 Fri, 06 Feb 2026 00:00:00 +0700 Multimode Evaluation of Pulmonary Rehabilitation in Newly Diagnosed Tuberculosis Patients using chest imaging, Respiratory Culture-Based Microbiome Profiling, and Inflammatory Biomarkers https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/279767 <p><strong>Objective</strong> Pulmonary rehabilitation (PR) plays a vital role in enhancing lung function and exercise capacity in individuals with pulmonary conditions. This study evaluated the clinical effectiveness of an 8-week PR program in newly diagnosed pulmonary tuberculosis (TB) patients through the assessment of lung function, exercise capacity, inflammatory biomarkers, and respiratory microbiome changes.</p> <p><strong>Methods </strong>Sixty newly diagnosed TB patients were enrolled, with 30 completing the 8-week PR program. Pulmonary function (FEV<sub>1</sub>, FVC, FEV<sub>1</sub>/FVC) and exercise capacity (6-minute walk test, 6MWT) were measured before and after PR. Inflammatory biomarkers (CRP, IL-6, TNF-a) and sputum microbiome profiles were assessed. ROC curves and multiple <br />regression models identified biomarkers that were predictive of functional improvement.</p> <p><strong>Results </strong>PR led to significant improvements: FEV<sub>1</sub> increased from 2.50 ± 0.60 L to 3.10 ± 0.50 L (<em>p</em> &lt; 0.001), FVC from 3.20 ± 0.70 L to 3.70 ± 0.60 L (<em>p</em> = 0.002), and 6MWT distance from 350.00 ± 40.00 m to 400.00 ± 50.00 m (<em>p</em> = 0.003). Oxygen saturation improved from 93.00 ± 2.00% to 95.00 ± 1.00% (<em>p</em> = 0.022). Inflammatory markers decreased significantly: CRP 18.00 ± 7.00 to 10.00 ± 5.00 mg/L (<em>p</em> &lt; 0.001), IL-6 25.00 ± 8.00 to 15.00 ± 6.00 pg/mL (<em>p</em> &lt; 0.001), and TNF-<img id="output" src="https://latex.codecogs.com/svg.image?\alpha&amp;space;" alt="equation" /> 50.00 ± 20.00 to 32.00 ± 15.00 pg/mL (<em>p</em> = 0.002). ROC analysis identified CRP as the strongest predictor of improvement (AUC = 0.84). Multiple regression confirmed CRP as an independent predictor of lung function and exercise capacity gains.</p> <p><strong>Conclusions </strong>An 8-week PR program significantly improved lung function, exercise capacity, and reduced systemic inflammation in TB patients, with CRP emerging as a key biomarker for predicting rehabilitation outcomes. </p> Leena Varghese, Sornambiga R, Visalatchi M, Dhanalakshmi M, Ramya Sakthivel, Muneefa K I Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/279767 Mon, 16 Mar 2026 00:00:00 +0700 The Effect of Dohsa-hou on Reducing Attention Deficit and Hyperactivity in 6- to 12-Year-Old Children and Adolescents https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275373 <p><strong>Objective</strong> To investigate the effect of Dohsa-hou relaxation on reducing attention deficit and hyperactivity.</p> <p><strong>Methods </strong>Eighty attention-deficit/hyperactivity disorder (ADHD) children aged 6-12 years were selected by the block randomization method and assigned to one of two groups, either the experimental or the control groups. The data collection tools included a demographic questionnaire, Conners’ parent rating scale and Conners’ (CPRS-RS) child attention deficit index.</p> <p><strong>Results </strong>The mean score of the children’s hyperactivity and attention deficit decreased after the intervention, which was statistically significant (<em>p</em> &lt; 0.001). The children’s hyperactivity scores were significantly different before and after the intervention in the two groups: a greater reduction was observed in the intervention group than in the control group. Although hyperactivity decreased in both groups, it was more pronounced in the intervention group (<em>p</em> &lt; 0.001). The comparison of children’s attention deficit scores before and after the intervention in the two groups also showed that Dohsa-hou treatment led to a more significant decrease in the scores of the intervention group (<em>p</em> &lt; 0.001).</p> <p><strong>Conclusion </strong>Dohsa-hou exercises can lead to reduced hyperactivity and attention deficit in most children with ADHD. </p> Maryam Amini, Reza Zeighami, Behzad Rigi, Amir Javadi Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275373 Mon, 16 Mar 2026 00:00:00 +0700 Antimutagenic Potential of Piper sarmentosum Leaf Extracts: Insights from Culinary Preparation https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/282093 <p><strong>Objective</strong> Piper sarmentosum Roxb., a traditional vegetable in Lanna and Thai cuisine, is valued for its flavor but its health-promoting properties after cooking remain unclear. This study investigated the phytochemical profiles, antioxidant capacity, and mutagenicity of its leaf extracts prepared to mimic typical culinary practices.</p> <p><strong>Methods </strong> Three P. sarmentosum extracts were prepared: an ethanolic extract of uncooked leaves (PEE), a hot water extract simulating curry broth (PHWE), and an ethanolic extract of boiled leaf residues representing the cooked leaves in curry (PREE). Their chemical composition, antioxidant activity, and antimutagenic effects were evaluated.</p> <p><strong>Results</strong> The extracts showed distinct phytochemical patterns. PEE and PREE were rich in phenolics and flavonoids, yielding strong antioxidant activity in ABTS and FRAP assays. PHWE contained higher levels of condensed tannins, reflecting the extraction of water-soluble compounds. None of the extracts showed mutagenicity in the Salmonella assay. Notably, PEE and PREE displayed significant antimutagenic activity against aflatoxin B1 (AFB<sub>1</sub>) in Salmonella typhimurium strains TA98 and TA100 with metabolic activation.</p> <p><strong>Conclusions</strong> P. sarmentosum leaves retain considerable antioxidant and antimutagenic potential after cooking, highlighting their value as a safe and functional food ingredient with potential health benefits. </p> Nichakarn Sanguankaew, Beilin Li , Sirinya Taya, Rawiwan Wongpoomchai, Orawan Khantamat Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/282093 Fri, 06 Feb 2026 00:00:00 +0700 Living Will Completion During Palliative Care Consultations and Factors Influencing Completion: A Retrospective Study in a University Hospital https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/282326 <p><strong>Objective</strong> To determine the proportion of palliative care patients completing a living will and to identify factors associated with completion.</p> <p><strong>Methods </strong>This retrospective study analyzed electronic medical records from Maharaj Nakorn Chiang Mai Hospital, a university hospital in Thailand. Patients who had their initial palliative care consultations between November 1, 2021 and April 30, 2022 were included. Descriptive statistics and multivariable logistic regression were used.</p> <p><strong>Results </strong>Of the 389 patients in the study, 205 (52.7%) were female, and the median age was 68 (IQR: 59–79). Most had cancer (67.6%) and poor performance status (PPS 10–30: 69.9%). Decision-making capacity was present in 177 patients (45.5%). A living will was introduced to 83 patients (21.3%) and was completed by 26 (6.7%). Higher PPS (70–100) were associated with being introduced to a living will. The most common reason for not introducing patients to a living will was poor patient symptom control. No factors were significantly associated with living will completion among those who were introduced to a living will.</p> <p><strong>Conclusions </strong>Most patients presented to palliative care with advanced disease and poor performance status, limiting opportunities for living will discussions and emphasizing the need for early consultation. Strengthening symptom management may support earlier and more frequent introduction of a living will, potentially improving completion rates. </p> Thawalrat Ratanasiri, Chanchanok Aramrat, Tanachon Uthaibutra, Nida Buawangpong, Wichuda Jiraporncharoen , Nisachol Dejkriengkraikul, Nutcha Vimolsutjarit, Tichakorn Changsantie, Achita Buarin Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/282326 Mon, 16 Mar 2026 00:00:00 +0700 In vitro Antioxidant, Acetylcholinesterase, and Amyloid-beta Inhibitory Effects of Captopril, An Angiotensin-Converting Enzyme (ACE) Inhibitor https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275569 <p><strong>Objective</strong> This study aims to investigate the potential of captopril, an angiotensin-converting enzyme (ACE) inhibitor, to reduce reactive oxygen species (ROS) production and address critical factors associated with Alzheimer’s disease (AD) pathology, including acetylcholinesterase (AChE) activity and amyloid-beta (A<sub><img src="https://latex.codecogs.com/svg.image?\beta&amp;space;" alt="equation" /></sub>) peptide aggregation. The broader goal was to explore captopril’s neuroprotective properties and its potential as a therapeutic agent for AD.</p> <p><strong>Methods </strong>The antioxidant effects of captopril were evaluated using DPPH and ABTS assays, as well as xanthine oxidase inhibition tests. The impact of captopril on AChE activity and A<strong><img src="https://latex.codecogs.com/svg.image?\ss&amp;space;" alt="equation" /></strong> aggregation was assessed through <em>in</em><em>-</em><em>vitro </em>experiments. Molecular docking studies were conducted to analyze captopril’s binding affinity with essential AD-related proteins.</p> <p><strong>Results </strong>Captopril demonstrated notable antioxidant activity with IC<sub>50</sub> values of 71.99±0.40 µM (DPPH) and 106.3±0.28 µM (ABTS), comparable to ascorbic acid (92.32 ± 0.26 µM and 110.1±0.24 µM). Significant inhibition of xanthine oxidase activity was observed; however, the IC<sub>50</sub> value exceeded the maximum tested concentration of 320 µM for both captopril and ascorbic acid. Captopril showed AChE inhibitory activity with an IC<sub>50</sub> of 208.2 ± 0.36 µM, whereas donepezil exhibited an IC<sub>50</sub> of 79.05 ± 0.25 µg/mL. In the A<sub><img src="https://latex.codecogs.com/svg.image?\beta&amp;space;" alt="equation" /></sub> aggregation assay, captopril had an IC<sub>50</sub> of 87.69±0.25 µM, while donepezil also displayed significant inhibition, with an IC<sub>50</sub> above 320 µM. Molecular docking analyses revealed favourable binding interactions of captopril with AChE and A<sub><img src="https://latex.codecogs.com/svg.image?\beta&amp;space;" alt="equation" /></sub>-related targets, supporting its multitarget mechanism.</p> <p><strong>Conclusions </strong>Captopril demonstrated notable neuroprotective effects, including antioxidant activity and the inhibition of AChE activity and A<sub><img src="https://latex.codecogs.com/svg.image?\beta&amp;space;" alt="equation" /></sub> aggregation. These findings indicate that captopril holds promise as a therapeutic agent for AD, warranting further research and clinical trials to evaluate its efficacy in combating neurodegeneration. </p> Raghul Murugan, Vantipalli Raga Sai Harshitha, Royapuram Parthasarathy Parameswari, Anitha Roy Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275569 Fri, 10 Apr 2026 00:00:00 +0700 Influence of the Frequency of Speech Therapy on the Velopharyngeal Gap in Cleft Lip and Palate Patients After Primary Palatoplasty https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/270963 <p><strong>Objective</strong> The craniofacial conditions of cleft lip and cleft palate (CLP) have been found to be common worldwide, especially in Asia and Thailand. Nevertheless, there are few studies of the association between the frequency of speech therapy and the impact on the velopharyngeal (VP) gap and speech outcome. This study aimed to evaluate the association between the frequency of speech therapy and the VP gap after primary palatoplasty.</p> <p><strong>Methods </strong>This retrospective cohort study collected data on 95 patients with CLP or isolated cleft palate who underwent primary palatoplasty at Maharaj Nakorn Chiang Mai Hospital between 2006 and 2018. Log risk regression analysis was carried out to identify the effect of frequency of speech therapy in reducing the VP gap including relative risk (RR) and 95% confidence interval (95%CI).</p> <p><strong>Results </strong>From univariable analysis, influence of speech therapy frequency on the presence of a VP gap showed a crude RR = 0.70 (95%CI = 0.49-0.98). Additionally, the frequency of speech therapy in the multivariable analysis showed an adjusted RR = 0.74, 95%CI = 0.46-1.19. The associated anomalies and syndromes showed a statistically significant correlation with a VP gap (adjusted RR = 1.60, 95%CI = 1.12-2.28).</p> <p><strong>Conclusion </strong>Patients who receive speech therapy 5-10 times or more showed a decrease in the incidence of a VP gap of at least 26%; however, this did not reach statistical significance. Nevertheless, it is recommended that speech therapy with cleft lip and cleft palate patients should be continued for at least 5 to 10 sessions.</p> Supitchaya Jaruvattanadilok, Chayada Kasirawat, Wasana Ko-iam, Nuntigar Sonsuwan, Krit Khwangern Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/270963 Fri, 10 Apr 2026 00:00:00 +0700 Comparison of Contrast-Enhanced MRI Using Hepatocyte-Specific Contrast with Contrast-Enhanced CT in Evaluation of Hepatobiliary Space-Occupying Lesions https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275735 <p><strong>Objective</strong> This study aimed to evaluate the diagnostic accuracy of multiphasic contrast-enhanced computed tomography (CECT) and contrast- enhanced magnetic resonance imaging (CEMRI) in assessing hepatic mass lesions.</p> <p><strong>Methods </strong>A cohort of 120 patients underwent imaging with both CEMRI and CECT to compare their diagnostic capabilities. Findings were analyzed for lesion size, enhancement patterns, sensitivity, specificity, and predictive values. Statistical tests were conducted to assess the significance of differences between the modalities, with <em>p</em>-values reported for critical metrics. To ensure consistency and minimize bias, a standardized imaging protocol was followed, and radiology experts independently reviewed all images.</p> <p><strong>Results </strong>CEMRI demonstrated higher sensitivity (90%) and specificity (87%) compared to CECT (85% and 80%, respectively), with statistically significant differences (<em>p</em> &lt; 0.05). CEMRI also outperformed CECT in posi-<br />tive predictive value (88% vs. 82%) and negative predictive value (90% vs. 84%). While the mean lesion size detected by CEMRI (4.0 ± 2.0 cm) was slightly smaller than that detected by CECT (4.4 ± 2.2 cm), the difference was not statistically significant (<em>p</em> = 0.45). Additionally, CEMRI identified 112 lesions compared to 108 lesions detected by CECT, further highlighting its superior diagnostic accuracy, particularly in detecting heterogeneous lesions.</p> <p><strong>Conclusion </strong>CEMRI outperforms CECT in diagnostic sensitivity, specificity, and predictive values, making it the preferred modality for lesion detection and characterization. However, both modalities performed similarly in assessing lesion size and total lesion count. These findings underscore the value of CEMRI in clinical scenarios requiring detailed lesion evaluation. Future studies with larger cohorts and a broader range of pathologies are recommended to confirm and extend these results for greater clinical applicability. </p> Vijay Pratap , Ankur Malhotra , Shruti Chandak Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/275735 Fri, 10 Apr 2026 00:00:00 +0700 Performance of Diagnostic Methods for Detection of Drug Resistance Among New Cases of Mycobacterium tuberculosis https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/277806 <p><strong>Objective</strong> The increasing incidence of new cases of drug resistant-TB (DR-TB) infection is worrisome, with high rates of new pulmonary morbidities occurring mostly among the vulnerable populations. The performance of diagnostic methods of GeneXpert MTB/RIF assay and phenotypic Drug Susceptibility Test (pDST) for detection of drug resistance among new cases of <em>Mycobacterium tuberculosis</em> (MTB) infections was evaluated.</p> <p><strong>Methods </strong>Sputum samples (n = 546) from newly suspected MTB cases were analysed for phenotypic drug resistance using BACTEC MGIT (B-MGIT) and genotyped with xpert MTB/RIF assay. The predictive performance of B-MGIT culture-based methods and xpert MTB/RIF assay for MTB detection were determined.</p> <p><strong>Results </strong>Of the collected sputum samples (n = 546), the highest rates of phenotypic drug resistance (66.7%) were AFB3+ smear positive and MTB with detection rates of 98.2% and 92.7%, respectively, with B-GMIT and Xpert MTB/RIF (<em>p</em> = 0.63). B-MGIT detected higher resistance rates to isoniazide (<em>inh</em>) and rifampicin (<em>rif</em>) of more than 60.0%, and less than 20% resistance to ofloxacin (ofx) and protionamide (proth) compared to Xpert (<em>p &lt; </em>0.05). B-MGIT had a higher detection rate (98.2%), sensitivity (87.8%), specificity (91.4%), positive predictive value (PPV) (95.8%) (95%CI: 0.778-1.04; <em>p</em> = 0.001) and likelihood of detection of rifampicin resistance (OR:5.76;95%CI:1.01-7.56) compared to Xpert MTB/RIF methods. B-MGIT provided higher AUC-rifampicin of 0.9339 (95%CI: 0.8398 to 1.000) than gene xpert (AUC-rifampicin = 0.9019 [95%CI: 0.7899 to 1.000]). B-MGIT is needed for further confirmation of new cases of MTB identified from acid-fast bacilli (AFB) smear positive sputum.</p> <p><strong>Conclusions </strong>The inclusion of B-MGIT examination of sputum in new TB cases would enhance early detection of drug resistant MTB, mostly from rifampicin negative sputum investigated with GeneXpert and mostly in low resource settings.</p> Paul A. Akinduti, Oluwaseun Ejilude, Oluwatoyin C. Ajanaku, Akinwande Kazeem, John O Akinbo, Olumuyiwa Emmanuel Olukayode, Chineye P. Nwaejigh, Zainab Ifeoluwani Adenekan, Akintunde A. Akinjinmi, Temitope T. Banjo Copyright (c) 2026 https://creativecommons.org/licenses/by/4.0/ https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/277806 Fri, 10 Apr 2026 00:00:00 +0700